Amrutanjan Health Care Ltd
Amrutanjan Health Care Q2 Results 2026 (FY27): Revenue ₹135.18 Cr, PAT ₹17.28 Cr
Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Based on Amrutanjan Health Care Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q2 FY27 Net Sales: ₹135.18 Crores, up 14.85% YoY (₹117.70 Crores in Q2 FY26). Quarter (Q2 FY27) Financials (Page 24):.
From Amrutanjan Health Care Ltd's Q2 FY27 earnings-call transcript · updated 3 Nov 2026.
How did Amrutanjan Health Care's revenue grow in the September 2026 quarter?
- Q2 FY27 Net Sales: ₹135.18 Crores, up 14.85% YoY (₹117.70 Crores in Q2 FY26)
- Q2 FY27 Profit Before Tax: ₹23.10 Crores, up 20.25% YoY (₹19.21 Crores in Q2 FY26)
- Q2 FY27 Profit After Tax: ₹17.28 Crores, up 23.78% YoY (₹13.96 Crores in Q2 FY26)
- Segment Sales Q2 FY27 (YoY growth):
- OTC: ₹90.94 Crores, +13.65% (₹80.02 Crores Q2 FY26)
- Women’s Hygiene & Personal Care: ₹40.48 Crores, +23.49% (₹32.78 Crores Q2 FY26)
2 more points from Amrutanjan Health Care Ltd's call on revenue
Create a free account to keep reading this call
What happened to Amrutanjan Health Care's margins in Q2 FY27?
See what Amrutanjan Health Care Ltd said on profitability & margins — free account, 30 seconds.
What capex is Amrutanjan Health Care planning?
- SAP implementation for new Comfy plant completed (Page 21).
- Sales Digitization initiatives including Distributor Management System and SAP Payroll Implementation are in progress (Page 21).
- Creation of infrastructure and working towards automation of processes in all possible areas mentioned as ongoing strategic pillars (Page 11).
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Amrutanjan Health Care raising money or cutting debt?
See what Amrutanjan Health Care Ltd said on fundraising & capital structure — free account, 30 seconds.
How big is Amrutanjan Health Care's order book?
See what Amrutanjan Health Care Ltd said on order book & pipeline — free account, 30 seconds.
Amrutanjan Health Care Ltd — Quarterly revenue & net profit
Q2 FY27 figures are not in this chart yet. Latest shown: Jun 2026 (Q1 FY27). The Q2 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q1 FY27): revenue ₹103 Cr, net profit ₹4 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Amrutanjan Healt's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Remus Pharmaceuticals (Q2 FY27)
Standalone Revenue (H1 FY27 vs H1 FY26):** ₹62.08 Cr vs ₹46.85 Cr, growth of 32.51% . Key results statement takeaways from Remus Pharmaceuticals Ltd's Q2 FY27 e
- Pfizer (Q2 FY27)
Revenue from operations for the quarter ended September 30, 2026: ₹726.86 crore (Page 3). Key results statement takeaways from Pfizer Ltd's Q2 FY27 results stat
- Aarti Drugs (Q2 FY27)
826.2 Crore, up 27% YoY from Rs. Key investor presentation takeaways from Aarti Drugs Ltd's Q2 FY27 investor presentation — and how it ranks against sector peer
- Anthem Bioscienc (Q2 FY27)
Q2FY27 Consolidated Revenue from Operations: ₹5,940 Mn, up 7.9% YoY from ₹5,505 Mn in Q2FY26 (Page 4). Key investor presentation takeaways from Anthem Bioscienc
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Amrutanjan Health Care Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Amrutanjan Health Care Ltd Q2 FY27 results?
Q2 FY27 Net Sales: ₹135.18 Crores, up 14.85% YoY (₹117.70 Crores in Q2 FY26). Quarter (Q2 FY27) Financials (Page 24):.
What is Amrutanjan Health Care Ltd share price analysis?
Amrutanjan Health Care Ltd currently shows a neutral. The stock trades at a P/E of 23.2 with a market cap of ₹1,441 Cr. Investors should review the full earnings analysis for detailed insights.
Is Amrutanjan Health Care Ltd planning capital expenditure?
SAP implementation for new Comfy plant completed (Page 21).
Keep Amrutanjan Health Care Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.